656 results match your criteria: "Los Angeles R.M.; and Johns Hopkins University[Affiliation]"
Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications.
Pharmacol Rev
March 2023
Department of Neurology, David Geffen School of Medicine (H.S.-K., I.S., R.M., G.B.), Brain Research Institute (G.B.), and Molecular Biology Institute (G.B.), University of California, Los Angeles, California; Department of Stem Cell Biology & Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California (G.R.L., J.I.); Department of Neurology, University of Michigan, Ann Arbor, Michigan (M.I.I.); Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany (T.W., J.M.); and Department of Computational Biochemistry (E.S.-G.) and Faculty of Chemistry (F-G.K., T.S.), University of Duisburg-Essen, Essen, Germany
Lysine-selective molecular tweezers (MTs) are supramolecular host molecules displaying a remarkably broad spectrum of biologic activities. MTs act as inhibitors of the self-assembly and toxicity of amyloidogenic proteins using a unique mechanism. They destroy viral membranes and inhibit infection by enveloped viruses, such as HIV-1 and SARS-CoV-2, by mechanisms unrelated to their action on protein self-assembly.
View Article and Find Full Text PDFComparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With .
Neurol Neuroimmunol Neuroinflamm
March 2023
From the Department of Neurology (R.M.), David Geffen School of Medicine at University of California Los Angeles; Kampala MRI Centre (S.K.L., M.K.), Uganda; Department of Radiological Sciences (N.S.), David Geffen School of Medicine, University of California Los Angeles, CA; Division of General Internal Medicine and Health Services Research (N.J.J.), David Geffen School of Medicine at UCLA; Centre of Tropical Neuroscience (P.R.A., R.A., R.I.), Kitgum Site, Uganda; Makerere University (R.A., R.J.O., R.I.), College of Health Sciences, Kampala, Uganda; Laboratory of Parasitic Diseases (J.K., T.N.), National Institutes of Health, Bethesda, MD; Centre for Tropical Medicine and Global Health (K.M., R.I.), Nuffield Department of Medicine, University of Oxford, United Kingdom; Department of Psychiatry (C.N.), University of Oxford, United Kingdom; and Nuffield Department of Clinical Neurosciences (A.V.), University of Oxford, United Kingdom.
Background And Objective: Nodding syndrome (NS) is a unique childhood-onset epileptic disorder that occurs predominantly in several regions of sub-Saharan Africa. The disease has been associated with -induced immune responses and possible cross-reactivity with host proteins. The aim of this study was to compare structural changes in the brain on MRI between NS and other forms of onchocerciasis-associated epilepsies (OAEs) and to relate structural changes to the Ov-induced immune responses and level of disability.
View Article and Find Full Text PDFPaging the Clinical Informatics Community: Respond STAT to Dobbs v. Jackson's Women's Health Organization.
Appl Clin Inform
January 2023
Department of Medicine, University of California San Francisco, San Francisco, California, United States.
Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study.
Ann Intern Med
January 2023
Cardiovascular Division, Department of Medicine, and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, Minnesota (L.Y.C, M.J.Z.).
Background: Atrial myopathy-characterized by changes in left atrial function and size-may precede and promote atrial fibrillation (AF) and cardiac thromboembolism. In people without prior AF or stroke, whether analysis of left atrial function and size can improve ischemic stroke prediction is unknown.
Objective: To evaluate the association of echocardiographic left atrial function (reservoir, conduit, and contractile strain) and left atrial size (left atrial volume index) with ischemic stroke and determine whether these measures can improve the stroke prediction achieved by CHADS-VASc score variables.
Dry Eye Subtypes in the Dry Eye Assessment and Management (DREAM) Study: A Latent Profile Analysis.
Transl Vis Sci Technol
November 2022
Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Purpose: Dry eye disease (DED) is a heterogeneous condition with poorly characterized subtypes. The DREAM study was a large multicenter randomized clinical trial that did not find omega-3 to be more effective than placebo in treating symptomatic DED. We performed secondary analysis of DREAM data to characterize DED subtypes and their omega-3 response.
View Article and Find Full Text PDFEvaluating the Impact of Assessment Metrics for Simulated Central Venous Catheterization Training.
Simul Healthc
February 2024
From the Departments of Mechanical and Nuclear Engineering (D.C.B., J.Z.M.) and Industrial and Manufacturing Engineering (J.M.G.-V., H.M.T.), The Pennsylvania State University; The Pennsylvania State University College of Medicine (E.H.S., S.D.A.), Hershey, PA; Cedars Sinai Medical Procedure Center and Vascular Access Services (P.K.N.); Cedars Sinai Medical Center (M.X.Y.), Los Angeles, CA; and Department of Engineering Design and Industrial Engineering (S.R.M.), The Pennsylvania State University, Hershey, PA.
Introduction: Performance assessment and feedback are critical factors in successful medical simulation-based training. The Dynamic Haptic Robotic Trainer (DHRT) allows residents to practice ultrasound-guided needle insertions during simulated central venous catheterization (CVC) procedures while providing detailed feedback and assessment. A study was performed to examine the effectiveness of the DHRT in training the important skills of needle tip tracking and aspiration and how these skills impact procedural complications in simulated CVC.
View Article and Find Full Text PDFNon-viral precision T cell receptor replacement for personalized cell therapy.
Nature
March 2023
PACT Pharma, South San Francisco, CA, USA.
Article Synopsis
- T cell receptors (TCRs) are crucial for T cells to detect cancer cell mutations, and researchers used a CRISPR-Cas9 method to edit TCR genes in a clinical trial setting.
- Sixteen patients with advanced solid cancers received personalized T cell therapies featuring engineered neoTCRs, with most participants experiencing either stable disease or disease progression.
- The study confirmed that it is feasible to create multiple engineered TCRs, showing the safety and effectiveness of infusing gene-edited T cells that can successfully target tumors.
Development of a core outcome set for quality of life for adults with drug-resistant epilepsy: A multistakeholder Delphi consensus study.
Epilepsia
January 2023
Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
Objective: In 2017, the American Academy of Neurology (AAN) convened the AAN Quality Measurement Set working group to define the improvement and maintenance of quality of life (QOL) as a key outcome measure in epilepsy clinical practice. A core outcome set (COS), defined as an accepted, standardized set of outcomes that should be minimally measured and reported in an area of health care research and practice, has not previously been defined for QOL in adult epilepsy.
Methods: A cross-sectional Delphi consensus study was employed to attain consensus from patients and caregivers on the QOL outcomes that should be minimally measured and reported in epilepsy clinical practice.
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia.
N Engl J Med
December 2022
From the Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine (A.F., M.F.V., J.A. Kalish, J.J.S.), the Division of Vascular and Endovascular Surgery (M.T.M., M.B.S.) and the Department of Medicine (N.K.C.), Brigham and Women's Hospital, Harvard Medical School (M.R.J.), and the Section of Vascular Medicine and Intervention, Massachusetts General Hospital (K.R.), Boston, HealthCore, Watertown (T.H.H., S.F.A., M.J.C., M.O., M.M.), and the Division of Vascular Surgery, UMass Memorial Health, Worcester (A.S.) - all in Massachusetts; the Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco (M.S.C., W.G., P.A.S.), the Division of Vascular Surgery, UC San Diego Health, La Jolla (A.B.), Coastal Cardiology, French Hospital Medical Center, San Luis Obispo (L.C.C.), and the Division of Vascular Surgery and Endovascular Therapy, University of Southern California, Los Angeles (V.L.R.) - all in California; the Department of Interventional Radiology (J.A. Kaufman) and the Division of Vascular Surgery, School of Medicine (A.A.), Oregon Health and Science University, and the Operative Care Division, Portland VA Medical Center (M.C.K.) - all in Portland; the Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH (R.J.P., M.A.C., P.P.G.); the Department of Medical Imaging, University of Arizona Health Sciences, Tucson (M.D.D.), and the Division of Vascular Surgery, Peak Heart and Vascular, Glendale (N.G.) - both in Arizona; the National Heart, Lung, and Blood Institute, Bethesda, MD (D.R., G.S.); the Medical Device Innovation Consortium, National Evaluation System for Health Technology Coordinating Center, Arlington, VA (F.S.S.); the Department of Cardiovascular Diseases, Ochsner Clinical School, University of Queensland, Brisbane, Australia (C.J.W.); the Department of Interventional Radiology, Gundersen Health System, La Crosse, WI (E.A.); the Iowa Heart Center, Des Moines (D.K.C.); the Division of Vascular Surgery, Centre Hospitalier Universitaire de Quebec-Université Laval, Quebec City (Y.D.), and Dalhousie University, Division of Cardiac and Vascular Surgery, Department of Surgery, Nova Scotia Health Association, Halifax (C.R.H.) - both in Canada; the Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta (L.F.); the Division of Vascular and Endovascular Surgery, Maine Medical Center, Portland (K.A.G.); the Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City (B.M.H.); Westchester Medical Center and the Department of Surgery, Section of Vascular Surgery, New York Medical College - both in Valhalla, NY (I.A.L.); the Vascular Medicine Outcomes Program, Yale University, New Haven, CT (C.M.-H.); the Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis (R.M.); and the Department of Vascular Surgery, University of Helsinki, and Helsinki University Hospital - both in Helsinki (M.V.).
Background: Patients with chronic limb-threatening ischemia (CLTI) require revascularization to improve limb perfusion and thereby limit the risk of amputation. It is uncertain whether an initial strategy of endovascular therapy or surgical revascularization for CLTI is superior for improving limb outcomes.
Methods: In this international, randomized trial, we enrolled 1830 patients with CLTI and infrainguinal peripheral artery disease in two parallel-cohort trials.
Novel treatment strategies are needed for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. This trial evaluated the feasibility and outcomes with the anti-CD19 bispecific T-cell-engaging antibody, blinatumomab, in combination with dasatinib and steroids. Patients 65 years of age or older with Ph+ or Ph-like ALL (with dasatinib-sensitive fusions/mutations) were eligible and could be newly diagnosed or relapsed/refractory.
View Article and Find Full Text PDFTwo Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
N Engl J Med
October 2022
From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, and Centre National de la Recherche Scientifique Unité Mixte de Recherche 5164, ImmunoConcept, Université de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris (K.E.) - all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) - both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) - both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount Sinai, New York (M.L.); Amsterdam University Medical Center, Amsterdam (A.W.); and Incyte, Wilmington, DE (D.K., K.S., K.B.).
Background: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo.
Methods: We conducted two phase 3, double-blind, vehicle-controlled trials (Topical Ruxolitinib Evaluation in Vitiligo Study 1 [TRuE-V1] and 2 [TRuE-V2]) in North America and Europe that involved patients 12 years of age or older who had nonsegmental vitiligo with depigmentation covering 10% or less of total body-surface area.
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
NPJ Breast Cancer
October 2022
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with first-line palbociclib plus an aromatase inhibitor (AI) versus an AI alone in routine US clinical practice. In total, 2888 patients initiated treatment during February 3, 2015-March 31, 2020, with a potential ≥6-month follow-up (cutoff date, September 30, 2020).
View Article and Find Full Text PDFStroke genetics informs drug discovery and risk prediction across ancestries.
Nature
November 2022
Bordeaux Population Health Research Center, University of Bordeaux, Inserm, UMR 1219, Bordeaux, France.
Previous genome-wide association studies (GWASs) of stroke - the second leading cause of death worldwide - were conducted predominantly in populations of European ancestry. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.
View Article and Find Full Text PDFRisk Factors for Colistin-Resistant Carbapenem-Resistant in the Postacute Care Setting.
Open Forum Infect Dis
September 2022
Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
We assessed risk factors for colistin resistance among carbapenem-resistant (CRKP) from 375 patients in long-term acute care hospitals. Recent colistin or polymyxin B exposure was associated with increased odds of colistin resistance (adjusted odds ratio = 1.11 per day of exposure, 95% confidence interval = 1.
View Article and Find Full Text PDFAn observation-first strategy for liver injuries with "blush" on computed tomography is safe and effective.
J Trauma Acute Care Surg
February 2023
From the Department of Surgery University of Colorado School of Medicine and Department of Trauma Service, University of Colorado Hospital, Anschutz Medical Campus (J.M.S., H.C., R.M.J., S.U., C.V.), Aurora, CO; Department of Surgery, UCSF-Fresno (S.B., R.C.D.), Fresno, CA; Trauma, Critical Care and Acute Care Surgery, Grant Medical Center (M.C.S., A.L.R.), Columbus, OH; Department of Surgery, University of California, San Francisco (M.S.F.), San Francisco, CA; Departments of Emergency Medicine and Surgery, Program in Trauma, R Adams Cowley Shock Trauma Center (D.M.S., D.J.H., H.A.), University of Maryland School of Medicine, Baltimore, MD; Graduate Medical Education, Methodist Dallas Medical Center (M.S.T., H.M.G.V.), Dallas, TX; Division of Trauma, Acute Care Surgery and Surgical Critical Care, Department of Surgery, Spartanburg Regional Medical Center (C.J.M., T.J.M.), Spartanburg, SC; Department of Surgery, University of Calgary (C.G.B.), Calgary, Alberta; Division of Acute Care Surgery, Loma Linda University Medical Center (K.M., G.M.), Loma Linda, CA; Department of Surgery (H.A.), University of Maryland School of Medicine, Baltimore MD; Department of Trauma and Acute Care Surgery, UCHealth Memorial Hospital (T.J.S., J.R.), Colorado Springs, CO; Department of Surgery, University of California Irvine (J.N., E.T.), Orange, California; Department of General Surgery, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem (M.B.), Jerusalem, Israel; Division of Trauma, Acute Care Surgery and Surgical Critical Care, Banner-University Medical Center Phoenix (N.K., M.C.), Phoenix, AZ; Department of Surgery, Division of Trauma and Critical Care, Cedars-Sinai Medical Center (N.K.D., E.J.L.), Los Angeles, CA; Department of Surgery, Cooper University Hospital (T.E., J.W.), Camden, NJ; Department of Surgery and Perioperative Care, Dell Medical School (T.C.P.C., V.E.), University of Texas at Austin, Austin, TX; Department of Surgery, Division of Trauma Acute Care Surgery, Banner Thunderbird Medical Center (K.P., K.C.), Glendale, AZ; Division of Trauma and Surgical Critical Care, Department of Surgery (S.B., F.S.E.), Rutgers New Jersey Medical School, Newark, NJ; Department of Trauma and Acute Care Surgery, Medical Center of the Rockies (W.D., C.P.), Loveland, CO; Department of Surgery, Denver Health Medical Center (N.L.W.), Denver, CO; Department of Trauma, Ascension Via Christi Saint Francis (J.M.H., K.L.), Wichita, KS; Department of Surgery, Miami Valley Hospital (G.S.), Wright State University, Dayton, OH; Department of Surgery, Prisma Health-Upstate (K.S.), Greenville, SC; and Department of Surgery, Boulder Community Hospital (L.A.H.), Boulder, CO.
Introduction: The management of liver injuries in hemodynamically stable patients is variable and includes primary treatment strategies of observation (OBS), angiography (interventional radiology [IR]) with angioembolization (AE), or operative intervention (OR). We aimed to evaluate the management of patients with liver injuries with active extravasation on computed tomography (CT) imaging, hypothesizing that AE will have more complications without improving outcomes compared with OBS.
Methods: This is a prospective, multicenter, observational study.
Artificial Intelligence for Contrast-Free MRI: Scar Assessment in Myocardial Infarction Using Deep Learning-Based Virtual Native Enhancement.
Circulation
November 2022
Oxford Centre for Clinical Magnetic Resonance Research (Q.Z., M.K.B., M.S., R.A.G., E.L., K.E.T., R.M., J.L.P., C.N., I.A.P., Y.P.L., S.G.M., O.R., S.N., S.K.P., V.M.F.), Radcliffe Department of Medicine, University of Oxford, United Kingdom.
Background: Myocardial scars are assessed noninvasively using cardiovascular magnetic resonance late gadolinium enhancement (LGE) as an imaging gold standard. A contrast-free approach would provide many advantages, including a faster and cheaper scan without contrast-associated problems.
Methods: Virtual native enhancement (VNE) is a novel technology that can produce virtual LGE-like images without the need for contrast.
Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study.
Neurology
November 2022
From the Department of Neurology (L.S., C.S., N.K., S.E., A.C., S.C., F.I., K.F., Shadi Yaghi), Brown University, Providence, RI; Department of Neurology (E.B.), University of Alabama at Birmingham; Department of Neurology (S.S.O.), University of Colorado School of Medicine, Aurora; Department of Neurology (J.G., J.A.), Washington University, Saint Louis, MO; Departments of Neurology (N.H., M.D.M.), and Psychiatry (N.H.), University of Massachusetts, Worcester; Department of Neurology (A.L.), Weill Cornell Medical Center, New York, NY; Department of Neurology (K.M., J.R.), Montefiore Medical Center, New York, NY; Department of Neurology (R.S., Yee Cheng, A.S.Z., A.H.), Yale University, New Haven, CT; Department of Neurology (Alexis Simpkins, G.L., J.K., D.P.), University of Florida, Gainesville; Department of Neurology (M.R.H., Adrian Scutelnic, R.M., B.S.), Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Neurology (A.R., O.K., D.D.), University of Pennsylvania, Philadelphia; Departments of Neurology (S.A.K., L.A.R.) and Neurosurgery (S.A.K.), Medical University of South Carolina, Charleston; Department of Neurology and Rehabilitation Medicine (E.A.M., Pooja Khatri, Y.A., B.C.), University of Cincinnati; Department of Neurology (D.K., H.L.), Vanderbilt University, Nashville, TN; Department of Neurology (T.N.N., Piers Klein, H.J.A.), Boston University School of Medicine, MA; Department of Neurology (J.A.F., L.K., S.A.), New York University, NY; Department of Neurology (V.M.), University of Utah, Salt Lake City; Department of Neurology (T.W., D.W.), Christchurch Hospital, New Zealand; Department of Neurology (A.N., D.A.), Hartford Hospital, CT; Department of Neurology (A.Q., J.M.), University of Kansas, Kansas City; Department of Neurology (M.K., Yao Cheng), Spectrum Health, Michigan State University, Grand Rapids, MI; Department of Neurology (B.M.G., M.W., D.R.), Duke University, Durham, NC; Department of Medicine and Surgery (M.C.V.), University of Perugia, Italy, University of Perugia, Italy; Neurology-Stroke Unit (Maurizio Paciaroni), IRCCS MultiMedica, Milano, Italy; Cooper Neurologic Institute (J.S., S.K., Siyuan Yu), Cooper University, Camden, NJ; Department of Neurology (C.L.G., E.A.), George Washington University, District of Columbia; Department of Neurology (G.M.D.M., T.D.), University Hospital Basel and University of Basel, Switzerland; Department of Interventional and Diagnostic Neuroradiology (A.B., Marios Psychogios), Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland; Department of Neurology (R.A.-D., T.K.-H., S.P.), University of Chicago, IL; and Department of Neurology (T.H., D.L.), University of California at Los Angeles.
Background And Objective: Cerebral venous thrombosis (CVT) is a rare cause of stroke carrying a nearly 4% risk of recurrence after 1 year. There are limited data on predictors of recurrent venous thrombosis in patients with CVT. In this study, we aim to identify those predictors.
View Article and Find Full Text PDFCerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.
N Engl J Med
October 2022
From the Department of Cardiovascular Medicine (S.R.K.), Cleveland Clinic Foundation (A.K.), Cleveland; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles (R. Makkar); Columbia Interventional Cardiovascular Care (M.L.), Columbia University Medical Center (S.K.), New York; Leipzig Heart Center, University of Leipzig, Leipzig (M.A.-W.), Medizinische Klinik und Poliklinik I, Klinikum der Universität München and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich (S.M.), Universitaetsklinikum Ulm, Ulm (W.R.), Medical Campus Lake Constance, Friedrichshafen (J.S.), and the Clinic for Internal Medicine and Cardiology, Technische Universität Dresden, Herzzentrum, Dresden (A.L.) - all in Germany; Pima Heart and Vascular, Tucson Medical Center Healthcare, Tucson, AZ (T.W.); Centennial Medical Center, Nashville (S.H.); Rigshospitalet, Copenhagen University Hospital, Copenhagen (L. Sondergaard); Heart Hospital of Austin, Austin (J.K.), Baylor Heart and Vascular Hospital, Dallas (R.C.S.), and Baylor Scott and White the Heart Hospital-Plano, Plano (K.H.) - all in Texas; Monash Medical Centre, Clayton, VIC, Australia (R.G.); Washington Hospital Center, Washington, DC (L. Satler); the Department of Neurology, University of Pennsylvania, Philadelphia (S.R.M.); Lahey Hospital and Medical Center, Burlington (S.J.B.), and Boston Scientific, Marlborough (R. Modolo, D.J.A., I.T.M.) - both in Massachusetts; Piedmont Heart Institute, Atlanta (V.H.T.); and the London School of Hygiene and Tropical Medicine, London (S.P.).
Background: Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may reduce the risk of stroke.
Methods: We randomly assigned patients with aortic stenosis in a 1:1 ratio to undergo transfemoral TAVR with CEP (CEP group) or without CEP (control group).
Differentiating between liver diseases by applying multiclass machine learning approaches to transcriptomics of liver tissue or blood-based samples.
JHEP Rep
October 2022
Department of Computer Science, University of California, Irvine, CA 92697, USA.
Background & Aims: Liver disease carries significant healthcare burden and frequently requires a combination of blood tests, imaging, and invasive liver biopsy to diagnose. Distinguishing between inflammatory liver diseases, which may have similar clinical presentations, is particularly challenging. In this study, we implemented a machine learning pipeline for the identification of diagnostic gene expression biomarkers across several alcohol-associated and non-alcohol-associated liver diseases, using either liver tissue or blood-based samples.
View Article and Find Full Text PDFAggressive or Moderate Fluid Resuscitation in Acute Pancreatitis.
N Engl J Med
September 2022
From the Departments of Gastroenterology (E.M., L.G., A.V.-R.) and Clinical Pharmacology (P.Z.), Dr. Balmis General University Hospital, ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante), Alicante, the Department of Clinical Medicine, Faculty of Medicine, Miguel Hernández University, Elche (E.M.), the Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá (A.G.G.P., M.Á.R.-G., J.D.-O.), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (P.Z., F.C.-S.), and the Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (F.C.-S.), Madrid, the Gastroenterology and Digestive Endoscopy Unit, Corporació Sanitària Parc Taulí, Sabadell (A.L.-A., L.P.L.), the Department of Gastroenterology, Hospital Clínico Universitario de Valencia, Valencia (P.N., A.M.S.-P.), the Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander (C.S.-M., M.C.), the Department of Gastroenterology, Hospital Dr. Negrín, Las Palmas (I.F.-C.), the Department of Gastroenterology, Miguel Servet University Hospital and Health Research Institute of Aragón, Zaragoza (D.C.D.), the Department of Gastroenterology, Central de Asturias University Hospital, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo (E.L.-B.), the Department of Gastroenterology, Lucus Augusti University Hospital, Lugo (E.M.-M.), the Department of Gastroenterology, Puerta del Mar University Hospital, Cadiz (L.M.C.-M.), and the Department of Gastroenterology, University Hospital of Navarre, Pamplona (V.U., M.G., F.B.) - all in Spain; the Division of Gastroenterology, University of Southern California, Los Angeles (J.L.B.); the Division of Epidemiology and Biostatistics, IRCSS European Institute of Oncology, Milan (P.M.); the General Surgery Unit, Department of Diseases of the Digestive Tract, Regional Hospital of High Specialty of Bajío, Leon, Mexico (E.E.L.-H., A.J.R.C.M.); and the Department of Gastroenterology, Surat Institute of Digestive Sciences Hospital and Research Center, Surat, India (R.M., R.T.).
Background: Early aggressive hydration is widely recommended for the management of acute pancreatitis, but evidence for this practice is limited.
Methods: At 18 centers, we randomly assigned patients who presented with acute pancreatitis to receive goal-directed aggressive or moderate resuscitation with lactated Ringer's solution. Aggressive fluid resuscitation consisted of a bolus of 20 ml per kilogram of body weight, followed by 3 ml per kilogram per hour.
Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms.
Neurology
November 2022
From the Division of Epilepsy and Clinical Neurophysiology (C.J.Y., C.H.), Department of Neurology, Boston Children's Hospital, MA; Department of Pediatrics (J.R.M.), Division of Pediatric Neurology, Nationwide Children's Hospital, The Ohio State University, Columbus; Division of Child Neurology (F.M.B.), Department of Neurology, Stanford University School of Medicine, Palo Alto, CA; Department of Neurology and ICCTR Biostatistics and Research Design Center (B.Z., S.L.), Boston Children's Hospital and Harvard Medical School, MA; Division of Child Neurology (D.S.), Department of Pediatrics, University of Arkansas for Medical Sciences, AR; Department of Pediatrics (S.A.H.), Division of Neurology, University of California, Los Angeles; Department of Neurology (E.G.Y.), Montefiore Medical Center, Bronx, NY; Jane and John Justin Neurosciences (C.G.K.), Cook Children's Hospital, Fort Worth, TX; Departments of Pediatrics and Neurology (C.J.), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora; Department of Pediatrics (R.K.S.), Division of Neurology, Atrium Health/Levine Children's, Charlotte, NC; Division of Pediatric Neurology (S. Bhatia), Department of Pediatrics, Medical University of South Carolina, Charleston; Department of Pediatrics (S. Bhalla), Division of Child Neurology, Emory University School of Medicine, Children's Healthcare of Atlanta, GA; and Department of Pediatrics (R.S.), Michigan Medicine, University of Michigan, Ann Arbor, MI.
Background And Objectives: Standard therapies (adrenocorticotropic hormone [ACTH], oral steroids, or vigabatrin) fail to control infantile spasms in almost half of children. Early identification of nonresponders could enable rapid initiation of sequential therapy. We aimed to determine the time to clinical remission after appropriate infantile spasms treatment initiation and identify predictors of the time to infantile spasms treatment response.
View Article and Find Full Text PDFPostvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD.
Inflamm Bowel Dis
June 2023
Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.
Methods: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.
Results: The study group included 594 patients (70% female, 58% BNT162b2).
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
Nat Commun
August 2022
Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Article Synopsis
- - Anti-SARS-CoV-2 monoclonal antibodies, like bamlanivimab, are important treatments for COVID-19, and their safety and effectiveness were tested in a study called ACTIV-2/A5401.
- - In this randomized trial, non-hospitalized adults with early COVID-19 symptoms were given either bamlanivimab or a placebo, but the primary results showed no significant differences in undetectable viruses or symptom improvement between the two groups.
- - Although bamlanivimab didn’t reduce symptom duration, it was linked to lower viral levels in the nose after three days and quicker drops in inflammation and viral levels, suggesting it may help control the virus's spread early on. *
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.
EBioMedicine
September 2022
Emory University, Atlanta, GA, United States. Electronic address:
Background: Better understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management.
Methods: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness.
Pediatric Emergency Medicine Fellowship Program Directors' Viewpoint: Minimum Levels of Entrustment for Graduating Fellows and Practicing Physicians to Perform the Subspecialty's Professional Activities.
Pediatr Emerg Care
August 2023
Division of Pediatric Critical Care Medicine, Harbor-UCLA Medical Center, The Lundquist Institute for Biomedical Innovation and David Geffen School of Medicine, Los Angeles, CA.
Objectives: Entrustable Professional Activities (EPAs) are essential tasks physicians perform within their professions. Entrustment levels that pediatric emergency medicine (PEM) fellowship program directors (FPDs) expect graduating fellows to achieve for PEM-specific and common pediatric subspecialty EPAs remain unreported. This study aims to determine minimum entrustment levels FPDs require fellows to achieve to graduate from fellowship and to compare FPD expectations for fellows versus practicing PEM physicians.
View Article and Find Full Text PDF